Drug intelligence / Profile preview

16055 NFL delta Gly4 trimer

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

16055 NFL delta Gly4 trimer is an HIV envelope (Env) protein trimer designed using structure-guided approaches to create a stable, native-like conformation of the HIV envelope glycoprotein. It is being developed as a potential HIV vaccine component, currently in Phase 1 clinical trials as part of heterologous prime-boost regimens combined with Trimer 4571, 3M-052-AF + Alum adjuvant, and Ad4-Env145NFL viral particles. The vaccine aims to elicit broadly neutralizing antibodies against HIV.

Other names: 16055 NFL delta Gly4 Env protein trimer

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on 16055 NFL delta Gly4 trimer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 16055 NFL delta Gly4 trimer.

Explore the full profile